KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Deffered Revenue (2021 - 2024)

Historic Non-Current Deffered Revenue for Travere Therapeutics (TVTX) over the last 4 years, with Q1 2024 value amounting to $888000.0.

  • Travere Therapeutics' Non-Current Deffered Revenue fell 8988.38% to $888000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $888000.0, marking a year-over-year decrease of 8988.38%. This contributed to the annual value of $1.8 million for FY2023, which is 8321.29% down from last year.
  • As of Q1 2024, Travere Therapeutics' Non-Current Deffered Revenue stood at $888000.0, which was down 8988.38% from $1.8 million recorded in Q4 2023.
  • Over the past 5 years, Travere Therapeutics' Non-Current Deffered Revenue peaked at $24.1 million during Q3 2021, and registered a low of $888000.0 during Q1 2024.
  • Over the past 4 years, Travere Therapeutics' median Non-Current Deffered Revenue value was $10.9 million (recorded in 2022), while the average stood at $11.6 million.
  • Per our database at Business Quant, Travere Therapeutics' Non-Current Deffered Revenue plummeted by 4635.86% in 2022 and then tumbled by 8988.38% in 2024.
  • Travere Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $20.4 million in 2021, then plummeted by 46.36% to $10.9 million in 2022, then tumbled by 83.21% to $1.8 million in 2023, then tumbled by 51.61% to $888000.0 in 2024.
  • Its last three reported values are $888000.0 in Q1 2024, $1.8 million for Q4 2023, and $4.6 million during Q3 2023.